{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-046920","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.279466+00:00","generated_at":"2026-05-30T01:40:41.661585+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Ocugen presents positive OCU400 clinical data: 84% less atrophy area in treated vs untreated","bullets":["OCU400 (AAV encoding NR2E3) shows restoration of phototransduction genes and improved retinal structure in multiple RP/LCA models.","Mean change in total atrophy area from baseline: +0.12 mm² treated vs +0.73 mm² untreated (84% improvement).","LL VA change from baseline: treated patients improved while untreated declined over 12 months.","Preclinical ERG and histology data show slowed degeneration across five animal models (Rho-/-, RhoP23H+/-, Rd7, Rd1, Rd16)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-046920","json":"https://secwatch.observer/filing/0001628280-24-046920.json","markdown":"https://secwatch.observer/filing/0001628280-24-046920.md","text":"https://secwatch.observer/filing/0001628280-24-046920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024046920/0001628280-24-046920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024046920/ocgn-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:40:41.661585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}